IPO Update: TiGenix Debuts In December After Motif Launched In November As 2016 Offerings Best 2015
Executive Summary
Motif Bio and TiGenix were the 29th and 30th biopharma IPOs in 2016 with the only first-time offerings for November and so far in December, but looking at performance so far this year, IPOs by therapeutics firms in 2016 continue to outperform 2015 offerings.
You may also be interested in...
Finance Watch: Here Come The IPOs Again As Bellus Raises $70m And Vir Joins The Queue
Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.
US IPOs In Review: Relatively Muted Market In 2016 To Continue In 2017
After biopharma initial public offerings in the US during 2016 outperformed the prior year’s IPOs, expect more of the same in 2017: fewer, but higher quality offerings at lower IPO share prices to keep values at acceptable levels for experienced health care investors.
VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Newly renamed Flagship Pioneering has raised a $285m venture capital fund to remain invested in portfolio companies as they grow. Also, 12 new and growing biopharma companies raised $657.15m.